Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Guillermo J. Ruiz-Delgado, MD, David Gomez Almaguer, MD, Luz C. Tarin-Arzaga, MD, Olga Cantú-Rodríguez, MD, Carlos Alarcon-Urdaneta, MD, Uxmal Rodriguez-Morales, MD, Jackeline Calderon-García, MD, Omar Fernandez-Vargas, MD, Maryel Montes-Montiel, MD, Monica Sanchez-Cardenas, MD, Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP (Glasg)

Blood (2012) 120 (21): 4892.

https://doi.org/10.1182/blood.V120.21.4892.4892

Published: 2012

Journal Articles

Low Incidence and severity of Graft-Versus-host disease after outpatient allogeneic Peripheral Blood Stem Cell Transplantation employing a Reduced-Intensity Conditioning

Olga Cantú-Rodríguez, MD, Juan A. Flores-Jiménez, MD, Cesar H Gutiérrez-Aguirre, MD, Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP, (Glasg), A López-Otero, MD, Consuelo Mancías-Guerra, MD, Oscar Gonzalez-Llano, MD, Oscar Treviño-Montemayor, Jose C. Jaime-Pérez, MD, Silvia Martínez-Cabriales, David Gomez-Almaguer, MD

Blood (2011) 118 (21): 4707.

https://doi.org/10.1182/blood.V118.21.4707.4707

Published: 2011

Journal Articles

Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft- Versus -Host Disease.

David Gomez-Almaguer, MD, Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP, Oscar Gonzalez-Llano, MD, Homero C. Gutierrez-Aguire, MD, Olga G. Cantu-Rodriguez, MD, Jose C. Jaime-Perez, MD, Sergio Giralt, MD

Blood (2007) 110 (11): 2983.

https://doi.org/10.1182/blood.V110.11.2983.2983

Published: 2007

Journal Articles

Transient Mixed Chimerism after Stem Cell Transplantation Can Induce Durable Molecular Complete Remissions in Chronic Myelogenous Leukemia.

Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP, David Gomez-Almaguer, MD, Guillermo J. Ruiz-Delgado, MD, Luz del Carmen Tarin-Arzaga, MD

Blood (2006) 108 (11): 5350.

https://doi.org/10.1182/blood.V108.11.5350.5350

Published: 2006

Journal Articles

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP(Glasg), David Gomez-Almaguer, MD, Amelia Morales-Toquero, MD, Cesar H. Gutierrez-Aguirre, Jorge Vela-Ojeda, Miriam A. Garcia-Ruiz-Esparza, MD, Carlos Manzano, MD, Amado Karduss, MD, Abraham Sumoza, MD, Carmino de-Souza, MD, Eliana Miranda, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 4838.

https://doi.org/10.1182/blood.V106.11.4838.4838

Published: 2005

NARROW

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Low Incidence and severity of Graft-Versus-host disease after outpatient allogeneic Peripheral Blood Stem Cell Transplantation employing a Reduced-Intensity Conditioning

Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft- Versus -Host Disease.

Transient Mixed Chimerism after Stem Cell Transplantation Can Induce Durable Molecular Complete Remissions in Chronic Myelogenous Leukemia.

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Low Incidence and severity of Graft-Versus-host disease after outpatient allogeneic Peripheral Blood Stem Cell Transplantation employing a Reduced-Intensity Conditioning

Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft- Versus -Host Disease.

Transient Mixed Chimerism after Stem Cell Transplantation Can Induce Durable Molecular Complete Remissions in Chronic Myelogenous Leukemia.

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only